← Back to headlines
Arbutus Biopharma Stock Surges on $230 Million Buyback Plan
Arbutus Biopharma stock surged significantly after the company announced a $230 million buyback plan. This move indicates confidence from the company and has been positively received by investors.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
